Low-molecular-weight heparins: Formulary drug class review

P and T

Volumn 26, Issue 9, 2001, Pages 486-492

  Rihn, T L ^a   Vanscoy, G J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

ANEMIA; BLEEDING; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULARY; DRUG HALF LIFE; DRUG INDICATION; DRUG LABELING; DRUG MARKETING; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; HEART MUSCLE ISCHEMIA; HEMATOMA; HUMAN; NEUROLOGIC EXAMINATION; REVIEW; THROMBOCYTOPENIA;

EID: 0034833537     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Pharmacokinetics of low molecular weight heparins in animal models
2. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina
3. Preclinical biochemistry and pharmacology of low molecular weight heparins in vivo-studies of venous and arterial thrombosis
4. From the Food and Drug Administration
5. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
6. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
7. Prevention of deep vein thrombosis after hip replacement-comparison between two low-molecular heparins, tinzaparin and enoxaparin
8. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients
9. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: A double-blind, randomized comparison
10. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
11. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism
12. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis
13. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism
14. Optimizing anticoagulant therapy in the management of pulmonary embolism
15. Outpatient treatment of pulmonary embolism with dalteparin
16. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency
17. Prevention of venous thromboembolism
18. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
19. Fragmin once or twice daily subcutaneously in the treatment of deep vein thrombosis of the leg
20. Subcutaneous enoxaparin once or twice daily compared to intravenous unfractionated heparin for treatment of venous thromboembolic disease
21. Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Fragmin in unstable coronary artery disease
22. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
23. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
24. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE Study. Efficacy and safety of subcutaneous enoxaparin in non-Q wave coronary events
25. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis
26. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?
27. Outcomes analyses of the outpatient treatment of venous thromboembolic disease using the low-molecular-weight heparin enoxaparin in a managed care organization
28. Comparative effectiveness of low-molecular-weight heparins after therapeutic interchange